A Randomized PhaseI/ II study of HSP70mRNA transfected Dendritic Cells for the the Adjuvant immunotherapy of Hepatocellular carcinoma

A Randomized PhaseI/ II study of HSP70mRNA transfected Dendritic Cells for the the Adjuvant immunotherapy of Hepatocellular carcinoma - H7DCAH study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010691

Enrollment

Registered

2013-05-11

Start date

2012-07-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Surgey and HSP70mRNA transfected Dendritic Cells for the the Adjuvant immunotherapy surgery alone

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diagnosed HCCs by dynamic CT or MRI and tumor markers 2. No therapy before 30 days for hepatectomy 3. R0 resection for Stage 2-4A (LIver cancer study group of Japan)

Exclusion criteria

Exclusion criteria: Without underlying diseases and allergy

Design outcomes

Primary

Measure	Time frame
1 year Desease-Free Survival rate	—

Secondary

Measure	Time frame
Safety Overall survival	—

Countries

Japan

Contacts

Public ContactShoichi Hazama

Yamaguchi University Graduate School of Medicibe Digestive Surgey and Surgical Oncology

hazama@yamaguchi-u.ac.jp+81-836-22-2264

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026